Quick Answer: The BALANCE Model is a CMS demonstration meant to give Medicare Part D and Medicaid a standardized, negotiated path to cover GLP-1 drugs (Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, and Foundayo) for both diabetes and weight management. Its Medicaid component launched May 1, 2026 and runs through December 31, 2031, with states able to opt in through January 1, 2027; as of September 2026, CMS had not publicly named a single participating state. Its Medicare Part D component, originally scheduled for January 1, 2027, was delayed indefinitely on April 21, 2026 because too few Part D plan sponsors signed on. In the meantime, the separate Medicare GLP-1 Bridge covers Wegovy, Zepbound, and Foundayo for $50 per month through December 31, 2027, outside the standard $2,100 Part D annual out-of-pocket cap. Without any of these programs, cash retail prices for BALANCE-listed GLP-1s run $149 to $1,349 per month in 2026, and manufacturer patient assistance programs from Novo Nordisk (NovoCare) and Eli Lilly (Lilly Cares Foundation) remain the fallback for uninsured patients at or below 400% of the federal poverty level.
The BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is a voluntary CMS Innovation Center demonstration announced in December 2025. Its purpose is to let CMS negotiate directly with manufacturers, on behalf of state Medicaid agencies and Medicare Part D plan sponsors, for lower net prices and standardized coverage rules on six GLP-1 drugs: Ozempic and Rybelsus (semaglutide for type 2 diabetes), Wegovy (semaglutide for weight management), Mounjaro (tirzepatide for type 2 diabetes), Zepbound (tirzepatide for weight management), and Foundayo (orforglipron, the once-daily oral GLP-1 the FDA approved April 1, 2026). Both Novo Nordisk and Eli Lilly agreed to participate. Coverage applies to beneficiaries with a body mass index of 30 or higher with a weight-related condition, a BMI of 35 or higher alone, or a BMI of 27 or higher with type 2 diabetes or cardiovascular disease, alongside a free manufacturer-funded lifestyle support program.
CMS opened the Medicaid side of BALANCE for state applications on May 1, 2026, with a rolling enrollment window that runs through January 1, 2027. States that participate must already be enrolled in the Medicaid Drug Rebate Program and may offer broader, but not narrower, eligibility than the federal criteria; nominal Medicaid cost-sharing rules cap most patient copays at $1 to $8 per prescription in 2026. As of September 2026, however, CMS had not publicly named a single confirmed participating state on the BALANCE Model page. That gap matters because only 13 states covered GLP-1s for obesity under fee-for-service Medicaid before BALANCE launched, down from 16 in 2025; California, New Hampshire, Pennsylvania, and South Carolina all dropped that coverage effective January 1, 2026. If you are on Medicaid, contact your state Medicaid agency directly to confirm whether it has opted into BALANCE and which of the six drugs it covers.
CMS projects Medicare coverage of GLP-1 weight-management drugs under a fully implemented BALANCE Model would cost $25 billion to $35 billion over 10 years, with Medicaid spending estimated near $15 billion total ($11 billion federal, roughly $4 billion state). The Medicare Part D component needed 80% of eligible plan sponsors to sign participation agreements; that threshold was not met, and CMS delayed the Medicare side of BALANCE indefinitely on April 21, 2026 rather than launch it January 1, 2027 as originally planned. In its place, the separate Medicare GLP-1 Bridge, a short-term Section 402 demonstration, launched July 1, 2026 and now runs through December 31, 2027. The Inflation Reduction Act separately selected semaglutide (Ozempic, Rybelsus, Wegovy) for Round 2 of Medicare drug price negotiation, with a negotiated Maximum Fair Price for the diabetes and cardiovascular indications taking effect January 1, 2027; that negotiated price applies regardless of whether BALANCE or the Bridge is running.
What BALANCE Model Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same balance model can cost many times more at a hospital than at your local pharmacy:
2026 BALANCE Model Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicaid BALANCE Model (participating states, 2026) | $1 - $8/prescription nominal copay | Live since May 1, 2026 but state opt-in status must be confirmed directly; no state was publicly confirmed as of September 2026. |
| Medicare GLP-1 Bridge (July 2026 - Dec 2027) | $50/month flat copay | Covers only Wegovy, Zepbound (KwikPen), and Foundayo for weight management; does not count toward the $2,100 Part D cap. |
| Standard Medicare Part D (2026, diabetes indication) | Formulary-tier copay, capped at $2,100/year | Applies to Ozempic, Mounjaro, and Rybelsus for type 2 diabetes; prior authorization is standard. |
| Pharmacy counter (retail, cash) | $149 - $1,349/month | Range depends on the specific drug, dose, and whether a manufacturer direct-pay program applies. |
| Manufacturer savings card (commercial insurance only) | $25 - $349/month | Blocked by federal anti-kickback law for Medicare, Medicaid, TRICARE, or VA beneficiaries. |
Costs reflect 2026 CMS program terms, GoodRx pricing, and manufacturer direct-pay programs. Confirm your state's BALANCE participation and your Bridge eligibility before assuming a price applies to you.
Source: CMS BALANCE Model, CMS Medicare GLP-1 Bridge, GoodRx, NovoCare, LillyDirect
Why Hospitals Charge So Much
CMS negotiates a confidential net price with manufacturers on behalf of participating Medicaid programs and, separately, sets a $245 per 30-day-supply net price under the Medicare GLP-1 Bridge. Neither figure is the price you see at a retail pharmacy counter. Cash retail prices run $149 to $1,349 per month in 2026 because they reflect the manufacturer's list price before any government-negotiated discount, and most retail pharmacy chains are not directly enrolled in a BALANCE or Bridge net-price arrangement the way a Medicaid claims system or the Bridge's central processor is.
Retail pharmacies that are not in-network for the Bridge's central processor will bill the full cash price even to an otherwise-eligible Medicare beneficiary, because the discount only applies when the claim routes through the correct system. Patients who assume any pharmacy automatically honors the $50 copay or the BALANCE net price are the most common source of billing surprises tied to these programs.
Inpatient hospital pharmacies rarely dispense these drugs since all six are self-administered outpatient prescriptions, but when a partial dose appears on a hospitalization bill, facility markups of two to four times the acquisition cost are common. Request the itemized bill and the National Drug Code to verify the charge against the 2026 wholesale acquisition cost for that specific drug.
Patient Assistance Programs
Four separate paths can lower what you pay for a BALANCE-listed GLP-1 in 2026, and which one applies depends on your coverage and where you live. Confirm your state and plan status before assuming any single figure applies to you.
Patient assistance programs for BALANCE Model| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Medicaid BALANCE Model | $1 - $8 nominal copay per prescription in participating states | medicaid.gov |
| Medicare GLP-1 Bridge | $50/month flat copay for Wegovy, Zepbound, or Foundayo through Dec 31, 2027 | medicare.gov/glp1bridge |
| NovoCare Patient Assistance Program (Novo Nordisk) | Free Ozempic, Wegovy, or Rybelsus for uninsured patients at or below 400% FPL | novocare.com/pap |
| Lilly Cares Foundation (Eli Lilly) | Free Mounjaro, Zepbound, or Foundayo for uninsured or denied-coverage patients at or below 400% FPL | lillycares.com |
Manufacturer copay savings cards are barred by federal anti-kickback law from anyone on Medicare, Medicaid, TRICARE, or VA benefits. If you have government coverage, the Bridge, the Medicaid BALANCE Model, or a manufacturer patient assistance program (not a manufacturer coupon) are your options instead.
Source: CMS BALANCE Model, CMS Medicare GLP-1 Bridge, NovoCare, Lilly Cares Foundation
Medicare Part D
Standard Medicare Part D does not cover GLP-1 drugs prescribed solely for weight loss by statute (the Medicare Prescription Drug, Improvement, and Modernization Act of 2003). Part D still covers Ozempic, Mounjaro, and Rybelsus when prescribed for type 2 diabetes, subject to formulary tier copays and the 2026 annual out-of-pocket cap of $2,100 across all Part D drugs combined.
The Medicare GLP-1 Bridge, launched July 1, 2026, operates outside the standard Part D benefit to close that weight-loss coverage gap for Wegovy, Zepbound, and Foundayo. The $50 monthly copay under the Bridge does not count toward TrOOP (true out-of-pocket costs) and does not benefit from Extra Help (Low-Income Subsidy) cost-sharing reductions, because the program sits outside the Part D benefit structure entirely.
The BALANCE Model's Medicare Part D component, once expected to replace the Bridge starting January 1, 2027, remains delayed indefinitely as of September 2026 because CMS did not reach its 80% Part D plan sponsor participation threshold. Had it launched, projected structures included a $50 monthly cost in enhanced or employer group plans, up to $125 in basic plans, and $0 after reaching a projected $2,400 out-of-pocket maximum in 2027. Until CMS revives or replaces it, Medicare beneficiaries needing weight-management coverage should rely on the Bridge through December 31, 2027.
Common BALANCE Model Billing Errors
Two federal demonstrations covering the same six drugs, layered over standard Part D and 50-state Medicaid variation, creates real room for billing mistakes. Check for these before paying an unexpected bill:
- Pharmacy not enrolled in the Bridge's central network billed the full $1,000+ cash price instead of processing the $50 copay. Ask the pharmacist to reroute the claim through the Bridge's central processor rather than your Part D plan's standard system.
- Ozempic or Mounjaro (diabetes-labeled) billed as if covered under the Bridge, which covers only the weight-management formulations: Wegovy, Zepbound, and Foundayo. Verify the dispensed NDC matches your prescription's indication.
- Medicaid claim denied at full retail price because your state has not confirmed BALANCE Model participation, but the pharmacy did not tell you before dispensing. Ask before filling, not after.
- Bridge $50 copay incorrectly counted toward your $2,100 Part D annual out-of-pocket cap. It should not, because the Bridge sits outside standard Part D benefit accounting.
- A manufacturer savings card applied on top of the Bridge or a state Medicaid claim. Stacking a commercial coupon with a federal program is not permitted and can trigger a clawback later.
- Extra Help (LIS) assumed to reduce the Bridge's $50 copay further. It does not; the Bridge copay is a flat rate regardless of LIS status.
Frequently Asked Questions
Is there a generic or biosimilar for the GLP-1 drugs covered by the BALANCE Model?
No. As of 2026, none of the six BALANCE-listed drugs (Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Foundayo) has an FDA-approved generic or biosimilar. Semaglutide's core patents expire around 2031, tirzepatide's extend into the early 2030s, and orforglipron (Foundayo), approved April 1, 2026, is protected into the early 2040s. Legally compounded versions largely disappeared after FDA ended the shortage designations in late 2024 and early 2025.
How do I apply for the Medicare GLP-1 Bridge or the BALANCE Model?
For the Medicare GLP-1 Bridge, check eligibility at medicare.gov/glp1bridge or call 1-800-MEDICARE and have your prescriber document your BMI and qualifying condition. For BALANCE's Medicaid component, call your state Medicaid agency directly, since CMS had not published a confirmed list of participating states as of September 2026. If neither applies to you, apply to NovoCare or the Lilly Cares Foundation instead.
Can I use a manufacturer savings card if I have Medicare or Medicaid?
No. Federal anti-kickback law bars manufacturer copay savings cards for anyone with Medicare, Medicaid, TRICARE, or VA benefits. Stacking a manufacturer coupon on top of the Bridge or a Medicaid claim is not permitted and can trigger a clawback. Your options instead are the Medicare GLP-1 Bridge, your state's BALANCE Model coverage, or the manufacturer's income-based patient assistance program.
What if Medicaid or the Medicare GLP-1 Bridge denies my GLP-1 prescription?
Request a written denial notice explaining the specific reason. If it is a Bridge prior authorization issue, ask your prescriber to resubmit to the Bridge's central processor rather than your Part D plan. If it is a standard Part D formulary tier denial, file a formal appeal within 60 days and request a step-therapy override. If your state has not opted into BALANCE, escalate through your state's Medicaid fair hearing process or apply to a manufacturer PAP.
Does the Inflation Reduction Act's negotiated price apply to BALANCE Model drugs?
Partly. Semaglutide (Ozempic, Rybelsus, Wegovy) was selected for Round 2 of Medicare drug price negotiation, with a negotiated Maximum Fair Price for the diabetes and cardiovascular indications taking effect January 1, 2027. That IRA negotiation is separate from and runs alongside BALANCE and the Bridge. Tirzepatide (Mounjaro, Zepbound) and orforglipron (Foundayo) have not yet been selected for negotiation because they have not been on the market long enough under current selection rules.
What does a BALANCE Model GLP-1 cost without insurance in 2026?
Cash retail prices for the six BALANCE-listed drugs run $149 to $1,349 per month in 2026, depending on the drug, dose, and pharmacy. Manufacturer direct-pay programs (NovoCare Pharmacy, LillyDirect) offer the lowest entry-level prices, from $149 to $499 per month, while traditional retail chains like Walgreens and Walmart typically charge closer to $1,000 to $1,349 for injectable pens without a coupon.
Do I qualify for the NovoCare or Lilly Cares patient assistance program?
You likely qualify if you are uninsured or have been denied coverage, are a US resident, have a valid prescription for one of the covered drugs, and your household income is at or below 400% of the federal poverty level, which is $63,840 for a single person or $132,000 for a household of four in 2026. Both programs require a signed application, proof of income, and either proof of no coverage or an insurance denial letter.
What is the difference between the BALANCE Model and the Medicare GLP-1 Bridge?
The BALANCE Model is the broader, longer-term CMS demonstration covering Medicaid (live May 2026 through December 2031, pending state opt-in) and a Medicare Part D component that was delayed indefinitely on April 21, 2026. The Medicare GLP-1 Bridge is a separate, shorter, interim program that launched July 1, 2026 specifically to fill the gap left by BALANCE's Medicare delay, offering a $50 monthly copay for Wegovy, Zepbound, and Foundayo through December 31, 2027.
